QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • For Ethically Minded Investors, International Stem Cell Corp. (ISCO) An Attractive Option 0 comments
    Oct 31, 2013 10:48 AM | about stocks: ISCO

    With their recent surge, biotechnology stocks have come to the attention of many investors, of whom many who are undoubtedly looking to see whether they could identify the next big biotechnological innovation and the surge in market performance along with it. But for investors concerned about the ethical side of their investments, these stocks may be a turn-off due to their potential to lead to what they consider to be medically unethical developments or other undesirable outcomes.

    International Stem Cell Corp., a company that has been increasingly noted for its potential to bring about the next wave of innovation in this industry, offers those exploring this area for investment opportunities a moral advantage. The opportunity lies in the company's powerful new stem cell technology, parthenogenesis. It uses unfertilized human eggs, or oocytes, to create parthenogenetic stem cells (hpSC stem cells) that can be used to treat millions of people with severe diseases of the eye, nervous system, or liver. Since these eggs are unfertilized, no viable embryo arises or undergoes destruction, allowing company investors to circumvent one of the hottest conflict focuses in medical ethics today.

    As a whole, International Stem Cell Corp. focuses on developing and commercializing promising biotechnological solutions to today's challenges in regenerative medicine. As parthenogenesis demonstrates, one of the channels by which the company seeks to foster new treatments is through development of new cell therapeutic solutions. Cell therapy has been clinically proven for treatment viability of serious afflictions in bodily locales including the already-mentioned eye, nervous system, or liver. However, it remains limited by the availability of safe immune-matched human cells. That is where parthenogenesis reveals its true value.

    Specifically, the hpSC stem cells that this technology engenders can be immune-matched to millions of people. With just a relative small line number of hpSC lines, treatment solutions could potentially extended to a large percentage of the global population.

    For more detailed information regarding the science behind parthenogenesis or International Stem Cell Corp.'s current biotechnological initiatives, please visit: internationalstemcell.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.